The story is two paragraphs:<p>Cerebral executives told its clinicians that the company will pause prescribing controlled substances like Adderall to treat attention deficit hyperactivity disorder beginning Monday, the company said.<p>Cerebral’s Co-Founder and Chief Executive Kyle Robertson made the announcement to staff in an email sent to staff this week, adding that the company will continue to treat existing ADHD patients.